CompletedPhase 2NCT00127504
Clinical Trial of Rifampin and Azithromycin for the Treatment of River Blindness
Studying Onchocerciasis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Centers for Disease Control and Prevention
- Principal Investigator
- Josef Amann, MD, MPHCDC/NCID/DPD
- Intervention
- Rifampin(drug)
- Enrollment
- 80 enrolled
- Eligibility
- 5 years · All sexes
- Timeline
- 2003 – 2004
Study locations (1)
- Universidad del Valle/MERTU, Guatemala City, Guatemala
Collaborators
Universidad del Valle, Guatemala · University of Alabama at Birmingham
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00127504 on ClinicalTrials.govOther trials for Onchocerciasis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06350851Development of a New Rapid Diagnostic Test to Support Onchocerciasis EliminationBioaster
- ACTIVE NOT RECRUITINGPHASE2NCT05180461Emodepside Phase II Trial for Treatment of OnchocerciasisDrugs for Neglected Diseases
- ACTIVE NOT RECRUITINGPHASE3NCT03876262Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for OnchocerciasisMedicines Development for Global Health